Why the study?
Pseudomyogenic hemangioendothelioma can be easily misinterpreted as other lesions with radically different treatment and prognosis due to its clinical and morphologic characteristics.
Key points are not available for this paper at this time.
Design
Review
PMH's relapsing multifocal behavior warrants extended surveillance; leaves open optimal management strategies for this rare entity.
Pseudomyogenic hemangioendothelioma (PMH) is a rare vascular tumor that presents more frequently in young adults and has a male predominance. It is usually located in the superficial or deep soft tissues of the extremities, but concurrent bone involvement can be present. In approximately two-thirds of patients this disease is multifocal, often involving multiple tissue planes. It is a relapsing lesion with low metastatic potential. Given its clinical and morphologic characteristics (multifocality, epithelioid morphology, absence of clearly evident vascular differentiation on hematoxylin-eosin slides), PMH can be easily misinterpreted as other lesions, often with radically different treatment and prognosis. For this reason, we think it is important to recognize this entity, which has some unique features. Here, we will briefly describe the clinical and pathologic features of PMH, detailing its more relevant differential diagnoses.
No takes yet. Share an insight, caveat, or question.
Caballero et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: